Expression and clinical significance of FOXM1, PLK1, HIF-1α and EZH2 in breast carcinoma
LIU Jing1, ZHOU Bingjuan2,MA Qiushuang2, CHEN Hong2, ZHANG Jinku2
1.Department of Pathology, General Hospital of Chinese People’s Armed Police Force, Beijing 100039, China; 2. Department of Pathology, the First Central Hospital of Baoding,Baoding 071000, China
Abstract：Objective To study the expressions and clinical significance of FOXM1, PLK1, HIF-1α and EZH2 in breast carcinoma.Methods Immunohistochemical staining was used not only to detect the expressions of FOXM1, PLK1, HIF-1α and EZH2 in 803 cases of invasive ductal breast carcinoma and para-tumor breast tissues, but also to evaluate the relationships between the expressions of FOXM1, PLK1, HIF-1α and EZH2 and the clinical pathological features of invasive ductal breast carcinoma, including the histological grade, lymph node metastasis and pTNM stage.Results Positive expression rates of FOXM1, PLK1, HIF-1α and EZH2 protein in invasive ductal breast carcinoma were 59.78%, 27.90%, 43.96% and 60.40% respectively, significantly higher than those in para-tumor breast tissues(29.89%, 0%, 3.86% and 20.92% respectively). There was a significant correlation between the expressions of FOXM1, PLK1, HIF-1α and EZH2 and the histopathological grade, lymph node metastasis and pTNM stage (P<0.05), but the expressions of FOXM1, PLK1, HIF-1α and EZH2 were not correlated with the patients’ age, menopause or tumor size. There was a significantly negative relationship between the expressions of PLK1, HIF-1α, EZH2 and ER. There was a significantly positive relationship between the expressions of Fox M1, EZH2 and HER-2 (P<0.01). The expressions of FOXM1, PLK1, HIF-1α and EZH2 in breast invasive ductal carcinoma were positively correlated(P<0.01).Conclusions The overexpressions of FOXM1, PLK1, HIF-1α and EZH2 may be involved in breast carcinogenesis and progression synergistically, and they might play an important role in the prognosis evaluation of breast carcinoma.
King S I, Purdie C A, Bray S E, et al. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome [J]. Breast Cancer Res, 2012, 14(2): R40.
[3]
Zhong H, De Marzo A M, Laughner E, et al. Overexpression of hypoxia-inducible factor- 1 alpha in common hum an cancers and their metastases [J]. Cancer Res, 1999, 59(22): 5830-5835.
Halasi M, Gartel A L. FOX(M1) news—it is cancer [J]. Mol Cancer Ther, 2013, 12(3): 245-254.
[6]
Park H J, Gusarova G, Wang Z, et al. Deregulation of FoxM1b leads to tumour metastasis [J]. EMBO Mol Med, 2011, 3(1): 21-34.
[7]
Millour J, Constantinidou D, Stavropoulou A V, et al. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance [J]. Oncogene, 2010, 29(20): 2983-2995.
[8]
Francis R E, Myatt S S, Krol J, et al. FoxM1 is a downstream target and marker of HER2 over expression in breast cancer [J]. Int J Oncol, 2009, 35(1): 57-68.
[9]
Wang G, Chen Q, Zhang X, et al. PCM1 recruits PLK1 to the pericentriolar matrix to promote primary cilia disassembly before mitotic entry [J]. J Cell Sci, 2013, 126(Pt6): 1355-1365.
[10]
Song B, Liu X S, Rice S J, et al. PLK1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer [J]. Mol Cancer Ther, 2013, 12(1): 58-68.
[11]
Zhang G, Zhang Z, Liu Z. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells [J]. Tumour Biol, 2013, 34(3): 1887-1894.
[12]
Maire V, Némati F, Richardson M, et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer [J]. Cancer Res, 2013, 73(2): 813-823.
[13]
Masoud G N, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy [J]. Acta Pharm Sin B, 2015, 5(5):378-389.
[14]
Cai F F, Xu C, Pan X, et al. Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer [J]. Oncotarget, 2016, 7(47): 77793-77806.
Kim K H, Kim L, Choi S J, et al. The clinicopathological significance of epithelial mesenchymal transition associated protein expression in head and neck squamous cell carcinoma [J]. Korean J Pathol, 2014, 48(4): 263-269.
[17]
Ernst T, Chase A J, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders [J]. Nat Genet, 2010, 42(8): 722-726.
[18]
Kleer C G, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells [J]. Proc Natl Acad Sci U S A, 2003, 100(20): 11606-11611.
[19]
Knudsen E S, Dervishaj O, Kleer C G, et al. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer [J]. Cell Cycle, 2013, 12(13): 2042-2050.
[20]
Myatt S S, Kongsema M, Man C W, et al. SUMOylation inhibits FOXM1 activity and delays mitotic transition [J]. Oncogene, 2014, 33(34): 4316-4329.
[21]
Fu Z, Malureanu L, Huang J, et al. Plk1-dependent phosphorylation of FOXM1 regulates a transcriptional programme required for mitotic progression [J]. Nat Cell Biol, 2008, 10(9): 1076-1082.
[22]
Mahara S, Lee P L, Feng M, et al. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer [J]. Proc Natl Acad Sci U S A, 2016, 113(26): E3735-E3744.
[23]
Cao P, Deng Z, Wan M, et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-11alpha/HIF-1beta [J]. Mol Cancer, 2010, 9: 108.
[24]
Riquelme E, Suraokar M, Behrens C, et al. VEGF/VEGFR-2 upregulatesEZH2 expression in lung adenocarcinoma cells and EZH2 depletionenhances the response to platinum-based and VEGFR-2-targeted therapy [J]. Clin Cancer Res, 2014, 20(14): 3849-3861.
[25]
Geng J, Li X, Zhou Z, et al. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer [J]. Cancer Lett, 2015, 359(2): 275-287.
2018, Vol. 29 
